ECYT is awaiting approval of its first drug (in ovarian cancer) from EMEA. It has a pivotal Phase III in process for FDA approval for the same drug in the same indication. It is partnered with Merck on all its oncology programs and MRK has promised to take the drug into four new cancer indications, all on MRK's dime. ECYT has a ton of cash. It's biomarker test will be approved in the next six months by the EMEA for use with its cancer drug. ECYT fully owns the rights to the biomarker test (probably worth $125-150 million/year in revenues). And you want to short this company????